Resmed(RMD)
$238.53+4.42 (+1.89%)
RMD
Resmed stock forecast
$238.53
At close:+4.42 (+1.89%)
Want to see RMD full AI Analyst Report?
Resmed (RMD) Stock Forecast & Price Target
1,214 Followers
RMD Analyst Ratings
Moderate Buy
4Buy8Hold0Sell
Based on 12 analysts giving stock ratings to Resmed in the past 3 months
RMD Stock 12 Month Forecast
Average Price Target
$261.73â–²(9.73% Upside)Based on 12 Wall Street analysts offering 12 month price targets for Resmed in the last 3 months. The average price target is $261.73 with a high forecast of $320.00 and a low forecast of $230.00. The average price target represents a 9.73% change from the last price of $238.53.
Past 12 Months12 Month ForecastJan2026Oct2026
High$320.00
Average$261.73
Low$230.00
Highest Price TargetHighest$320.00Average Price Target$261.73Lowest Price TargetLowest$230.00
Detailed List of Analyst Forecasts​
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Article | |||||||
|---|---|---|---|---|---|---|---|---|
| Laura Sutcliffe | Citi | $240→$270 | hold | 13.19%Upside | Reiterated | 11/02/26 | ||
| Lyanne Harrison | Bank of America Securities | $320 | buy | 34.16%Upside | Reiterated | 11/02/26 | ||
| Brett Fishbin | KeyBanc | $267→$277 | buy | 16.13%Upside | Reiterated | 10/30/26 | ||
| Nathan Treybeck | Wells Fargo | $215→$250 | hold | 4.81%Upside | Assigned | 10/30/26 | ||
| David Rescott | Robert W. Baird | $238→$246 | hold | 3.13%Upside | Reiterated | 10/30/26 | ||
| Craig Wong-Pan | RBC Capital | $262→$288 | buy | 20.74%Upside | Reiterated | 10/30/26 | ||
| Anthony Petrone | Mizuho Securities | $240→$270 | buy | 13.19%Upside | Reiterated | 10/30/26 | ||
| Michael Matson | Needham | ― | hold | ― | Reiterated | 10/30/26 | ||
| Adam Maeder | Piper Sandler | $225→$260 | hold | 9.00%Upside | Reiterated | 10/30/26 | ||
| David Bailey | Morgan Stanley | $233 | hold | -2.32%Downside | Reiterated | 10/30/26 | ||
| Jonathan Block | Stifel Nicolaus | $235 | hold | -1.48%Downside | Reiterated | 10/02/26 | ||
 Jackson PhilipsNot Ranked | Rothschild & Co Redburn | $230 | hold | -3.58%Downside | Initiated | 08/19/26 | ||
| Brandon Vazquez | William Blair | ― | buy | ― | Reiterated | 08/07/26 | ||
| Unknown AnalystNot Ranked | Oppenheimer | ― | hold | ― | Assigned | 08/07/26 | ||
| Matthew Taylor | Jefferies | $225 | hold | -5.67%Downside | Reiterated | 07/10/26 |
| Rating | Article | ||||
|---|---|---|---|---|---|
| Laura SutcliffeCiti | HoldReiterated$240→$270 | 11/02/26 | 13.19%Upside | ||
| Lyanne HarrisonBank of America Securities | BuyReiterated$320 | 11/02/26 | 34.16%Upside | ||
| Brett FishbinKeyBanc | BuyReiterated$267→$277 | 10/30/26 | 16.13%Upside | ||
| Nathan TreybeckWells Fargo | HoldAssigned$215→$250 | 10/30/26 | 4.81%Upside | ||
| David RescottRobert W. Baird | HoldReiterated$238→$246 | 10/30/26 | 3.13%Upside | ||
| Craig Wong-PanRBC Capital | BuyReiterated$262→$288 | 10/30/26 | 20.74%Upside | ||
| Anthony PetroneMizuho Securities | BuyReiterated$240→$270 | 10/30/26 | 13.19%Upside | ||
| Michael MatsonNeedham | HoldReiterated | 10/30/26 | ― | ||
| Adam MaederPiper Sandler | HoldReiterated$225→$260 | 10/30/26 | 9.00%Upside | ||
| David BaileyMorgan Stanley | HoldReiterated$233 | 10/30/26 | -2.32%Downside | ||
| Jonathan BlockStifel Nicolaus | HoldReiterated$235 | 10/02/26 | -1.48%Downside | ||
| Jackson PhilipsRothschild & Co RedburnNot Ranked | HoldInitiated$230 | 08/19/26 | -3.58%Downside | ||
| Brandon VazquezWilliam Blair | BuyReiterated | 08/07/26 | ― | ||
| Unknown AnalystOppenheimerNot Ranked | HoldAssigned | 08/07/26 | ― | ||
| Matthew TaylorJefferies | HoldReiterated$225 | 07/10/26 | -5.67%Downside |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering Resmed
3 Months
Success Rate15/24 ratings generated profit
63%
Average Return
+3.92%
Copying Anthony Petrone's trades and holding each position for 3 Months would result in 62.50% of your transactions generating a profit, with an average return of +3.92% per trade.
1 Year
Success Rate17/24 ratings generated profit
71%
Average Return
+10.79%
Copying Anthony Petrone's trades and holding each position for 1 Year would result in 70.83% of your transactions generating a profit, with an average return of +10.79% per trade.
2 Years
Success Rate10/16 ratings generated profit
63%
Average Return
+4.77%
Copying Brett Fishbin's trades and holding each position for 2 Years would result in 62.50% of your transactions generating a profit, with an average return of +4.77% per trade.
RMD Analyst Recommendation Trends
| Rating | Jul 26 | Aug 26 | Sep 26 | Oct 26 | Nov 26 |
|---|---|---|---|---|---|
| Strong Buy | 3 | 2 | 1 | 0 | 0 |
| Buy | 12 | 13 | 10 | 10 | 7 |
| Hold | 16 | 16 | 17 | 15 | 9 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 31 | 31 | 28 | 25 | 16 |
In the current month, RMD has received 7 Buy Ratings, 9 Hold Ratings, and 0 Sell Ratings. RMD average Analyst price target in the past 3 months is 261.73.
RMD Financial Forecast
High$3.13
Consensus$2.99
Low$2.93
RMD Earnings Forecast
Next quarter’s earnings estimate for RMD is $2.99 with a range of $2.93 to $3.13. The previous quarter’s EPS was $2.91. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
High$1.48B
Consensus$1.46B
Low$1.44B
RMD Sales Forecast
Next quarter’s sales forecast for RMD is $1.46B with a range of $1.44B to $1.48B. The previous quarter’s sales results were $1.41B. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
RMD Stock Forecast FAQ
What is RMD’s average 12-month price target, according to analysts?
Based on analyst ratings, Resmed’s 12-month average price target is $261.73.
What is RMD’s upside potential, based on the analysts’ average price target?
Resmed has 9.73% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is RMD a Buy, Sell or Hold?
Resmed has a consensus rating of Moderate Buy which is based on 4 buy ratings, 8 hold ratings and 0 sell ratings.
What is Resmed’s price target?
The average price target for Resmed is $261.73. This is based on 12 12-month price targets, issued in the past 3 months. The highest analyst price target is $320.00, the lowest forecast is $230.00. The average price target represents a 9.73% increase from the current price of $238.53.
What do analysts say about Resmed?
Resmed’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 12 Wall Street analysts.
How can I buy shares of RMD?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
